Azenta, Inc. (NASDAQ:AZTA) Shares Bought by Zions Bancorporation N.A.

Zions Bancorporation N.A. increased its stake in Azenta, Inc. (NASDAQ:AZTA) by 15.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,678 shares of the company’s stock after purchasing an additional 3,774 shares during the quarter. Zions Bancorporation N.A.’s holdings in Azenta were worth $1,384,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Ballentine Partners LLC raised its position in shares of Azenta by 2.0% during the 4th quarter. Ballentine Partners LLC now owns 20,340 shares of the company’s stock worth $1,017,000 after buying an additional 404 shares in the last quarter. Picton Mahoney Asset Management raised its holdings in Azenta by 305.7% during the fourth quarter. Picton Mahoney Asset Management now owns 706 shares of the company’s stock worth $35,000 after purchasing an additional 532 shares in the last quarter. Glenmede Trust Co. NA lifted its position in Azenta by 6.3% in the third quarter. Glenmede Trust Co. NA now owns 11,379 shares of the company’s stock worth $551,000 after purchasing an additional 679 shares during the period. KBC Group NV boosted its stake in Azenta by 48.5% during the 4th quarter. KBC Group NV now owns 2,137 shares of the company’s stock valued at $107,000 after purchasing an additional 698 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund increased its position in shares of Azenta by 7.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 10,700 shares of the company’s stock valued at $535,000 after purchasing an additional 702 shares during the period. Institutional investors own 99.08% of the company’s stock.

Azenta Trading Down 2.8 %

NASDAQ AZTA opened at $37.15 on Wednesday. Azenta, Inc. has a 1 year low of $35.56 and a 1 year high of $63.58. The stock’s 50-day moving average price is $46.13 and its two-hundred day moving average price is $46.49. The company has a market cap of $1.70 billion, a PE ratio of -12.47 and a beta of 1.52.

Azenta (NASDAQ:AZTA) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.05 by $0.03. Azenta had a negative net margin of 24.91% and a positive return on equity of 1.25%. Research analysts forecast that Azenta, Inc. will post 0.53 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on AZTA shares. TD Cowen upgraded Azenta to a “hold” rating in a report on Thursday, February 27th. Evercore ISI upped their price target on shares of Azenta from $50.00 to $52.00 and gave the company an “in-line” rating in a report on Thursday, February 6th. Stephens reaffirmed an “overweight” rating and issued a $60.00 price objective on shares of Azenta in a research note on Thursday, January 2nd. Finally, Needham & Company LLC raised their target price on shares of Azenta from $55.00 to $59.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $58.75.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.